• Presence and degree of nausea and vomiting in the acute and delayed phases after oxaliplatin-based chemotherapy as recorded in the patient's diary over days 1-5 [ Designated as safety issue: Yes ]
  
• Impact of nausea and vomiting on the patient's quality of life as measured by the Functional Living Index - Emesis scale at baseline and at 5-7 days [ Designated as safety issue: Yes ]
  
• Comparison of this study's findings with those from aprepitant-containing anti-emetic studies conducted with cisplatin-containing regimens [ Designated as safety issue: No ]
  
• Investigation of potential factors predisposing patients to nausea and vomiting (e.g., gender, age, prior chemotherapy experience, or tendency toward development of motion-sickness) [ Designated as safety issue: No ]
  

OBJECTIVES:

• To assess the prevalence of delayed nausea and vomiting in patients with colorectal cancer receiving standard anti-emetic medications during the first course of an oxaliplatin-based chemotherapy regimen (mFOLFOX6 or FOLFOX7).

OUTLINE: This is a multicenter study.

Patients undergo collection of demographic, diagnostic, and treatment data at baseline. Patients complete the Functional Living Index-Emesis (FLIE) questionnaire at baseline prior to first chemotherapy infusion and at 5-7 days. Patients also fill out daily patient diaries about symptoms of nausea and vomiting, and use of medications to prevent these symptoms over days 1-5.